COX-2 and neurodegeneration in Parkinson's disease

Peter Teismann, M Vila, D-K Choi, K Tieu, D C Wu, V Jackson-Lewis, S Przedborski

Research output: Contribution to journalArticlepeer-review

163 Citations (Scopus)


Parkinson's disease (PD) is a common neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Recent observations link cyclooxygenase type-2 (COX-2) to the progression of the disease. Consistent with this notion, studies with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) show that inhibition and ablation of COX-2 markedly reduce the deleterious effects of this toxin on the nigrostriatal pathway. The similarity between this experimental model and PD strongly supports the possibility that COX-2 expression is also pathogenic in PD.
Original languageEnglish
Pages (from-to)272-277
Number of pages6
JournalAnnals of the New York Academy of Sciences
Publication statusPublished - 1 Jun 2003


  • Animals
  • Anti-Inflammatory Agents
  • Cyclooxygenase 2
  • Humans
  • Isoenzymes
  • MPTP Poisoning
  • Membrane Proteins
  • Mice
  • Nerve Degeneration
  • Parkinson Disease
  • Prostaglandin-Endoperoxide Synthases
  • Substantia Nigra
  • Thiazines
  • Thiazoles
  • inflammation
  • neurotoxicity
  • neurodegeneration
  • MPTP
  • Parkinson's disease
  • reactive oxygen species
  • superoxide dismutase


Dive into the research topics of 'COX-2 and neurodegeneration in Parkinson's disease'. Together they form a unique fingerprint.

Cite this